Cervical Cancer Diagnostics Market By Test (Pap Smear Test, Colposcopy, HPV Testing, Cervical Cancer Biopsy & Others), By Point Of Care (Hospital, Laboratories, Clinics, Independent Physician, Others), Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global cervical cancer diagnostics market is expected to grow at the CAGR of 5% during 2016-2022. Cervical cancer happens in cells of the cervix due to abnormal cell growth. Continuous spread of human papillomavirus (HPV) infection mainly in the females, rising incidents of weak immune system, and frequent use of oral contraceptive pills are the main factors responsible for the growth of cervical cancer diagnostic tests market. Changes in life style such as smoking, and multiple sex partners having genetic cervical cancers are anticipated to drive the global market in the near future. Lack of proper technology, equipment, healthcare infrastructure and other facilities in developing nation pose as a major challenge to the growth of the global cervical cancer diagnostic market. Lack of primary healthcare infrastructure and facilities and non availability of such facilities in the developing countries such as Brazil, India, and China, and high cost of treatments are also major challenges. Many patients avoid screening because of high hospitalization costs. Lack of awareness regarding women’s diseases and improper operating facilities in most of the developing country is a major reason for high female mortality in these regions. In most the regions, people do not have any knowledge about cervical cancer and the screening that must be done for its early detection. There are two predominant types of cervical cancers that are mostly found and diagnosed in women; they are squamous cell carcinoma and adenocarcinoma. Rising prevalence of human papillomavirus infected patients globally and growing teenage sexual encounter incident rates are two of the most common reasons for the growth of this market. Apart from this, increasing number of world obesity patients and female smokers is also expected to enhance the market growth during the years in future. The technological advancements, computer-guided and well equipped screening tests for cervical cancer, for reducing the rate of false-negative results, and improving no error solution are expected to contribute to the growth of the cervical cancer diagnostic market during the forecast period 2016 to 2022.
Market Segment Insights
Cervical cancer diagnostics market is segmented on the basis of tests conducted for the diagnosis of cancer patients and by point of care. There are different types of tests such as Pap smear tests, endocervical curettage procedure (ECC) colposcopy, HPV testing, and biopsy. A Pap smear is done by microscopic testing of the cells collected through the cervix of uterus. Pap smear test is the largest opted low cost test. Endocervical curettage is done by testing scraped mucous membrane of the cervix. Colposcopy is a procedure for testing an illuminated, magnified view of the cervix using a device called colposcopy. HPV testing is done using techniques of molecular biology of nucleic acid probes. By point of care, it is diagnostics by hospitals, clinics, independent physician, laboratories etc. According to the World Health Organization (WHO), deaths due to cervical cancer are more than 270,000 annually and it is growing year by year mainly in the developing countries. Rising use of cervical cancer diagnostic tests such as colposcopy, Pap smear tests and HPV testing for early detection, are the reason for high growth rate and also for highly competitive market.
Regional Insights
On the basis of geography, North America has the largest share of the total cervical cancer diagnostic tests and diagnostics market. However, Asia Pacific countries such as Australia, Thailand, India Japan, South Korea, Malaysia, and China are showing remarkable growth rate due to emerging economies and growing markets. Also the government initiatives and support for awareness about the diagnosis of cervical cancer, funding for the awareness and increasing disposable income in these developing countries are further fuelling the global market. However, favorable support from governments and healthcare agencies for healthcare infrastructure would enhance the growth of the cervical cancer diagnostic market in Asia Pacific region.
Competitive Insights
Some of the key players operating in global cervical cancer diagnostics market include, Abbott Laboratories, Arbor Vita Corporation, Becton, Biolight Meditech, EDP Biotech, Extract Science, Genomic Tree, Roche Diagnostics, Qiagen N.V., and Siemens Healthcare. These companies are operating globally and are trying to capture more market share in this tough competition. Strategic acquisitions, technological developments and heavy expenditure on R&D are the major reasons for the growth of the global cervical cancer diagnostic market. Abbott Laboratories in 2014 acquired a company Veropharm, which is a leading Russia-based pharmaceutical company. This acquisition allowed Abbott Laboratories to get Veropharm’s large portfolio of medicines and are thus getting huge market share in the competitive market.
CHAP 1. METHODOLOGY & SCOPE 12
1.1. RESEARCH METHODOLOGY 12
1.2. RESEARCH SCOPE & ASSUMPTIONS 12
1.3. LIST OF DATA SOURCES 12
CHAP 2. EXECUTIVE SUMMARY 13
2.1. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET SUMMARY & KEY BUYING CRITERIA 13
2.2. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET OUTLOOK 13
2.3. MARKET SEGMENTATION ANALYSIS 13
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 13
2.5. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET VALUE CHAIN ANALYSIS 13
2.6. VENDOR LANDSCAPE 13
CHAP 3. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET 14
3.1. MARKET DRIVER ANALYSIS 14
3.2. MARKET RESTRAINT ANALYSIS 14
3.2.2. CHANGES IN REGULATORY GUIDELINES 14
3.3. KEY OPPORTUNITIES 14
3.3.1. GOVERNMENT INITIATIVES AND SUPPORT 14
3.4. CHALLENGES 14
CHAP 4. INDUSTRY ANALYSIS 15
4.1. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET– PORTER’S FIVE FORCE MODEL 15
4.2. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET– PESTEL ANALYSIS 15
4.3. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET– GAP ANALYSIS 15
CHAP 5. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY TEST 2012-2022 ($ MILLION) 16
5.1. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY PAP SMEAR TEST 2012-2022 ($ MILLION) 16
5.2. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY COLPOSCOPY 2012-2022 ($ MILLION) 16
5.3. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY HPV TESTING 2012-2022 ($ MILLION) 16
5.4. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY CERVICAL CANCER BIOSPY 2012-2022 ($ MILLION) 16
5.5. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ MILLION) 16
CHAP 6. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY POINT OF CARE 2012-2022 ($ MILLION) 17
6.1. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY HOSPITAL 2012-2022 ($ MILLION) 17
6.2. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY LABORATORIES 2012-2022 ($ MILLION) 17
6.3. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY CLINICS 2012-2022 ($ MILLION) 17
6.4. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY INDEPENT PHYSICIAN 2012-2022 ($ MILLION) 17
6.5. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ MILLION) 17
CHAP 7. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 18
7.1. GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY REGION 2012-2022 ($ MILLION) 18
7.2. NORTH AMERICA 18
7.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
7.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.2.3.1. U.S. 18
7.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.2.3.2. CANADA 18
7.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.3. EUROPE 18
7.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
7.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.3.3.1. GERMANY 18
7.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.2. UK 19
7.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.3. FRANCE 19
7.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.4. REST OF EUROPE 19
7.3.3.4.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 19
7.3.3.4.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 19
7.4. ASIA PACIFIC 19
7.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 19
7.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.4.3.1. CHINA 19
7.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.4.3.2. INDIA 19
7.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.3. JAPAN 20
7.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.4. OTHERS 20
7.4.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($ MILLION) 20
7.4.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 20
7.5. MIDDLE EAST & AFRICA 20
7.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.6. LATIN AMERICA 20
7.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
CHAP 8. COMPETITIVE LANDSCAPE 21
8.1. ABBOTT DIAGNOSTICS 22
8.1.1. COMPANY OVERVIEW 22
8.1.2. SCOT ANALYSIS 22
8.1.3. PRODUCT BENCHMARKING 22
8.1.4. STRATEGIC INITIATIVES 22
8.2. ARBOR VITA CORPORATION 22
8.2.1. COMPANY OVERVIEW 22
8.2.2. SCOT ANALYSIS 22
8.2.3. PRODUCT BENCHMARKING 22
8.2.4. STRATEGIC INITIATIVES 22
8.3. AUTOGENOMICS 22
8.3.1. COMPANY OVERVIEW 22
8.3.2. SCOT ANALYSIS 22
8.3.3. PRODUCT BENCHMARKING 22
8.3.4. STRATEGIC INITIATIVES 22
8.4. BECTON DECKINSON AND COMPANY 22
8.4.1. COMPANY OVERVIEW 22
8.4.2. SCOT ANALYSIS 22
8.4.3. PRODUCT BENCHMARKING 22
8.4.4. STRATEGIC INITIATIVES 22
8.5. BIOLIGHT MEDITECH 22
8.5.1. COMPANY OVERVIEW 22
8.5.2. SCOT ANALYSIS 22
8.5.3. PRODUCT BENCHMARKING 22
8.5.4. STRATEGIC INITIATIVES 22
8.6. CANCER GENETICS 22
8.6.1. COMPANY OVERVIEW 23
8.6.2. SCOT ANALYSIS 23
8.6.3. PRODUCT BENCHMARKING 23
8.6.4. STRATEGIC INITIATIVES 23
8.7. COMPANION DX 23
8.7.1. COMPANY OVERVIEW 23
8.7.2. SCOT ANALYSIS 23
8.7.3. PRODUCT BENCHMARKING 23
8.7.4. STRATEGIC INITIATIVES 23
8.8. COOPER SURGICAL 23
8.8.1. COMPANY OVERVIEW 23
8.8.2. SCOT ANALYSIS 23
8.8.3. PRODUCT BENCHMARKING 23
8.8.4. STRATEGIC INITIATIVES 23
8.9. EDP BIOTECH 23
8.9.1. COMPANY OVERVIEW 23
8.9.2. SCOT ANALYSIS 23
8.9.3. PRODUCT BENCHMARKING 23
8.9.4. STRATEGIC INITIATIVES 23
8.10. EXACT SCIENCES 23
8.10.1. COMPANY OVERVIEW 23
8.10.2. SCOT ANALYSIS 23
8.10.3. PRODUCT BENCHMARKING 23
8.10.4. STRATEGIC INITIATIVES 23
8.11. GENOMIC TREE 23
8.11.1. COMPANY OVERVIEW 23
8.11.2. SCOT ANALYSIS 23
8.11.3. PRODUCT BENCHMARKING 23
8.11.4. STRATEGIC INITIATIVES 24
8.12. METABIOMICS 24
8.12.1. COMPANY OVERVIEW 24
8.12.2. SCOT ANALYSIS 24
8.12.3. PRODUCT BENCHMARKING 24
8.12.4. STRATEGIC INITIATIVES 24
8.13. QIAGEN N.V 24
8.13.1. COMPANY OVERVIEW 24
8.13.2. SCOT ANALYSIS 24
8.13.3. PRODUCT BENCHMARKING 24
8.13.4. STRATEGIC INITIATIVES 24
8.14. ROCHE 24
8.14.1. COMPANY OVERVIEW 24
8.14.2. SCOT ANALYSIS 24
8.14.3. PRODUCT BENCHMARKING 24
8.14.4. STRATEGIC INITIATIVES 24
8.15. SIEMENS HEALTHCARE 24
8.15.1. COMPANY OVERVIEW 24
8.15.2. SCOT ANALYSIS 24
8.15.3. PRODUCT BENCHMARKING 24
8.15.4. STRATEGIC INITIATIVES 24
TABLE 1 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY TEST 2012-2022 ($ MILLION) 24
TABLE 2 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY PAP SMEAR TEST 2012-2022 ($ MILLION) 24
TABLE 3 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY COLPOSCOPY 2012-2022 ($ MILLION) 25
TABLE 4 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY HPV TESTING 2012-2022 ($ MILLION) 25
TABLE 5 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY CERVICAL CANCER BIOSPY 2012-2022 ($ MILLION) 25
TABLE 6 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ MILLION) 25
TABLE 7 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY POINT OF CARE 2012-2022 ($ MILLION) 25
TABLE 8 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY HOSPITAL 2012-2022 ($ MILLION) 25
TABLE 9 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY LABORATORIES 2012-2022 ($ MILLION) 25
TABLE 10 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY CLINICS 2012-2022 ($ MILLION) 25
TABLE 11 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY INDEPENT PHYSICIAN 2012-2022 ($ MILLION) 25
TABLE 12 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ MILLION) 25
TABLE 13 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY REGION 2012-2022 ($ MILLION) 25
TABLE 14 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 25
TABLE 15 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 25
TABLE 16 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 25
TABLE 17 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 25
TABLE 18 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 25
TABLE 19 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 25
TABLE 20 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 25
TABLE 21 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 22 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 26
TABLE 23 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 24 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 25 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 26 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 27 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 28 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 29 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 30 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 26
TABLE 31 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 32 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 26
TABLE 33 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 34 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 35 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 36 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 37 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 38 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 39 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 40 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($ MILLION) 27
TABLE 41 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 42 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 43 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 44 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 45 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
FIGURE 1 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY PAP SMEAR TEST 2012-2022 ($ MILLION) 27
FIGURE 2 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY COLPOSCOPY 2012-2022 ($ MILLION) 27
FIGURE 3 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY HPV TESTING 2012-2022 ($ MILLION) 27
FIGURE 4 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY CERVICAL CANCER BIOSPY 2012-2022 ($ MILLION) 27
FIGURE 5 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ MILLION) 27
FIGURE 6 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY HOSPITAL 2012-2022 ($ MILLION) 27
FIGURE 7 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY LABORATORIES 2012-2022 ($ MILLION) 27
FIGURE 8 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY CLINICS 2012-2022 ($ MILLION) 28
FIGURE 9 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY INDEPENT PHYSICIAN 2012-2022 ($ MILLION) 28
FIGURE 10 GLOBAL CERVICAL CANCER DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ MILLION) 28
FIGURE 11 MARKET SHARE BY REGIONS 28
FIGURE 12 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 13 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 14 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 15 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 16 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 17 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 18 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 19 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 20 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 21 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 22 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 23 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)